Troxerutin attenuates isoproterenol-induced cardiac hypertrophy via the LKB1/AMPK/mTOR pathway

Panminerva Med. 2021 Jun;63(2):233-234. doi: 10.23736/S0031-0808.19.03676-0. Epub 2019 Jul 25.

Authors

Junfa Zhao¹, Daoli Chen², Chuanwei Feng³

Affiliations

¹ Department of Cardiovascular Medicine, Zhucheng People's Hospital, Zhucheng, China.
² Department of Cardiothoracic Surgery, Zhucheng People's Hospital, Zhucheng, China.
³ Department of Cardiovascular Medicine, Zhucheng People's Hospital, Zhucheng, China - zhao.junfa@163.com.

PMID: 31352760
DOI: 10.23736/S0031-0808.19.03676-0

No abstract available

MeSH terms

AMP-Activated Protein Kinases / metabolism*
Animals
Anticoagulants / pharmacology
Cardiomegaly / chemically induced
Cardiomegaly / prevention & control*
Hydroxyethylrutoside / analogs & derivatives*
Hydroxyethylrutoside / pharmacology
Isoproterenol / adverse effects*
Rats
TOR Serine-Threonine Kinases / metabolism*

Substances

Anticoagulants
Hydroxyethylrutoside
troxerutin
MTOR protein, human
TOR Serine-Threonine Kinases
AMP-Activated Protein Kinases
Isoproterenol